SIRT6 and metabolic syndrome: Therefore Sirt6 could be a potential target in the treatment of dyslipidemia (Tao et al., 2013a; Chaudhary et al., 2017; Glerup et al., 2017; Handelsman and Lepor Norman, 2018; Spolitu et al., 2019).